European shares ended a busy results week higher, with the DAX up 2.53% to 25,818.21 and the STOXX 600 up 1.73%. Company figures did most of the work. Stellantis jumped 15.38% on Wednesday after its revenue beat forecasts, while Adyen sank 13.35% the same day after cutting its margin target. Spain's IBEX 35 was the exception, down 1.77% as Santander slid.
Paris kept pace with Frankfurt, the CAC 40 gaining 2.4%, and Milan's FTSE MIB rose 1.94%. London's FTSE 100 lagged with a 0.37% gain. The week reversed much of the previous one, when the STOXX 600 lost 1.39% and the DAX 1.72%.
| Index | Close | Week |
|---|---|---|
| STOXX 600 | 646.75 | +1.73% |
| EURO STOXX 50 | 6,131.31 | +1.04% |
| DAX | 25,818.21 | +2.53% |
| CAC 40 | 7,969.42 | +2.40% |
| FTSE MIB | 49,501 | +1.94% |
| FTSE 100 | 10,729.80 | +0.37% |
| IBEX 35 | 18,652.90 | -1.77% |
Stellantis Wins Back a Lost Week in One Day
Stellantis was the week's standout. The shares rose 15.38% on Wednesday 28 October and finished the week up 16.5% at €4.14, recovering all of the previous week's 10.82% fall.
Third-quarter revenue rose 1% to €37.6bn, against a consensus of €35.9bn, even though shipments fell 1%. Adjusted operating income rose to €256m from €90m, a margin of only 0.7%, but the direction was what investors wanted. North America swung to an adjusted operating profit of €64m from a loss of €475m a year earlier. The adjusted loss per share narrowed to €0.01 from €0.04.
The company reaffirmed its 2026 outlook and its goal of positive industrial free cash flow in 2027. Chief executive Antonio Filosa said cost cuts should speed up in the fourth quarter and through 2027, and that Stellantis expects to beat its initial €2.4bn savings target. He also warned of significant inflation in raw materials and memory chips.
Weak spots remain. Industrial free cash flow was still negative at €4.0bn in the quarter, only €0.3bn better than a year earlier, and the enlarged Europe region lost €311m against a profit of €157m a year before.
Stellantis: share price, chart and news
Adyen Pays for a Margin Cut
The Dutch payments group had the opposite reaction to a strong quarter. Net revenue rose 23% to €738.1m, ahead of the company-compiled consensus of €730.3m, and processed volume grew 30% to €451.1bn, against an expected €435.6bn.
The problem was the outlook. Adyen now expects a 2026 EBITDA margin of 50%, which Reuters reported as a cut from about 52%, and it dropped its medium-term EBITDA objective altogether, saying it wanted to retain flexibility. Co-chief executive Ingo Uytdehaage tied the change to heavier hiring as Adyen moves into billing and loyalty products, with 1,000 to 1,100 new staff planned this year. Analysts at Degroof Petercam called the new outlook "clearly a nasty surprise", coming one quarter after guidance was last updated.
The shares fell 13.35% on Wednesday and 12.53% over the week to €826.90, leaving them down roughly 40% this year, according to Reuters. The revenue growth target of 21% to 23% at constant currency stands, capital spending stays at 7% of net revenue, and a new chief financial officer, Niclas Neglen, is due to start on 1 February 2027.
Santander Drags Madrid Lower
Santander fell 12.09% over the week to €10.12, the main reason the IBEX 35 went the other way from the rest of Europe. The bank reported on 28 October that ordinary net profit for the first nine months rose 16.1% to €11.18bn, and net interest income rose 9.5% to €34.5bn, but income from financial operations fell 34.7%. The shares were down 3.69% at €10.85 in mid-morning trading that day and kept falling. Chief executive Héctor Grisi blamed a negative bias among investors, kept the 2026 profit target of more than €15bn and said he expected a CET1 capital ratio above 12.8%.
Winners and Losers
Among tracked European-listed stocks:
| Stock | Week | Close |
|---|---|---|
| Stellantis | +16.50% | €4.14 |
| Bayer | +15.01% | €50.58 |
| AstraZeneca | +8.86% | £139.60 |
| Adyen | -12.53% | €826.90 |
| Santander | -12.09% | €10.12 |
| HSBC | -5.55% | £12.77 |
Bayer's rally came after a St. Louis County jury found for its Monsanto unit on all claims in the Aretino Roundup case on 29 October, the first Roundup trial since the US Supreme Court's Durnell ruling in June. The company reports third-quarter results on 3 November. AstraZeneca rose 6.96% on Friday after third-quarter core earnings of $2.79 a share beat forecasts of $2.59.
In New York, Alphabet's 12.64% fall on Thursday, covered in a separate report, weighed on US technology shares.
What Comes Next
The coming week brings more results, with Bayer and Ferrari both reporting on 3 November. For Stellantis the test is whether the cost savings Filosa promised show up in fourth-quarter cash flow. For Adyen it is the 2027 outlook due with full-year results in February.
Sources
- TIKR: Stellantis soars 14% on Q3 revenue beat and guidance promising positive industrial free cash flow in 2027
- Webull (Benzinga): Stellantis third-quarter results
- Adyen: Adyen publishes Q3 2026 business update
- Euronext (Reuters): Adyen shares drop 12% as lower margin target overshadows revenue beat
- Demócrata: Santander falls almost 4% on the stock market despite earning 11,176 million through September
- Demócrata: Santander maintains its target of 15 billion in 2026
- BCLP: BCLP team helps secure defense verdict in first Roundup trial since Supreme Court ruling
- Devdiscourse (Reuters): AstraZeneca CEO strikes bullish tone on pipeline as stock rallies
- BMK News market data (delayed exchange data)








